Overview
Indications
® Clinical Studies (14) [see]. LIMITED POPULATION: DEFENCATHis indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure r
Contraindications
When this intervention should not be used
DEFENCATH is contraindicated in patients with: Warnings and Precautions (5.1) [see] Known heparin-induced thrombocytopenia (HIT). Warnings and Precautions (5.2) [see]. Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH) or pork products
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
32 trials linked to this intervention
Recent Trials
International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures
Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)
Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin
Cystic Fibrosis and Totally Implantable Vascular Access Devices
Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Heparin (substance)
- SNOMED CT
- 372877000
- UMLS CUI
- C0019134
- RxNorm CUI
- 5224
- Labeler
- CorMedix Inc.
Clinical Data
This intervention maps to 15 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.